Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer

Yoshihiko Segawa, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Yoshio Hiraki, Yoichi Watanabe, Toshiro Yonei, Tomonori Moritaka, Junichiro Hiyama, Shunkichi Hiraki, Mitsune Tanimoto, Mine Harada

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To improve the efficacy of a combination of cisplatin and etoposide and concurrent accelerated twice-daily thoracic radiotherapy against limited-stage small-cell lung cancer, we conducted a phase I/II study using an altered schedule of chemotherapy administration. Chemotherapy consisted of four cycles of cisplatin (days 1 and 8) and etoposide (days 1, 2, 8, and 9) every 4 weeks. Accelerated hyperfractionated thoracic radiation (1.5 Gy twice daily×30 fractions, total dose of 45 Gy) was concurrently given with the first cycle of chemotherapy. The recommended doses of cisplatin and etoposide determined in the phase I study were 40 and 80 mg/m2, respectively. In the phase II study, the overall response rate was 100% (complete response: 32%, partial response: 68%). By a median follow-up time of 29 months, median radiation-outfield progression-free survival was 13.4 months, while radiation-infield progression-free survival did not reach median value. The median overall survival time was 22.9 months, with survival rate of 48.4% at 2 years. Major toxicities were leukopenia and neutropenia (≥grade 3, 92% each). The local control and overall survival demonstrated in this study were excellent. However, the insufficient distant control suggests a need for development of more active chemotherapy regimens.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalLung Cancer
Volume41
Issue number1
DOIs
Publication statusPublished - Jul 1 2003

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cisplatin
Appointments and Schedules
Radiotherapy
Thorax
Drug Therapy
Disease-Free Survival
Radiation
Radiation Dosage
Leukopenia
Neutropenia

Keywords

  • Accelerated hyperfractionated thoracic radiation
  • Cisplatin
  • Concurrent chemoradiotherapy
  • Etoposide
  • Limited-stage small-cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. / Segawa, Yoshihiko; Ueoka, Hiroshi; Kiura, Katsuyuki; Tabata, Masahiro; Takigawa, Nagio; Hiraki, Yoshio; Watanabe, Yoichi; Yonei, Toshiro; Moritaka, Tomonori; Hiyama, Junichiro; Hiraki, Shunkichi; Tanimoto, Mitsune; Harada, Mine.

In: Lung Cancer, Vol. 41, No. 1, 01.07.2003, p. 13-20.

Research output: Contribution to journalArticle

Segawa, Yoshihiko ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Takigawa, Nagio ; Hiraki, Yoshio ; Watanabe, Yoichi ; Yonei, Toshiro ; Moritaka, Tomonori ; Hiyama, Junichiro ; Hiraki, Shunkichi ; Tanimoto, Mitsune ; Harada, Mine. / Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. In: Lung Cancer. 2003 ; Vol. 41, No. 1. pp. 13-20.
@article{802d7600332245bf9da34c00f9f058f0,
title = "Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer",
abstract = "To improve the efficacy of a combination of cisplatin and etoposide and concurrent accelerated twice-daily thoracic radiotherapy against limited-stage small-cell lung cancer, we conducted a phase I/II study using an altered schedule of chemotherapy administration. Chemotherapy consisted of four cycles of cisplatin (days 1 and 8) and etoposide (days 1, 2, 8, and 9) every 4 weeks. Accelerated hyperfractionated thoracic radiation (1.5 Gy twice daily×30 fractions, total dose of 45 Gy) was concurrently given with the first cycle of chemotherapy. The recommended doses of cisplatin and etoposide determined in the phase I study were 40 and 80 mg/m2, respectively. In the phase II study, the overall response rate was 100{\%} (complete response: 32{\%}, partial response: 68{\%}). By a median follow-up time of 29 months, median radiation-outfield progression-free survival was 13.4 months, while radiation-infield progression-free survival did not reach median value. The median overall survival time was 22.9 months, with survival rate of 48.4{\%} at 2 years. Major toxicities were leukopenia and neutropenia (≥grade 3, 92{\%} each). The local control and overall survival demonstrated in this study were excellent. However, the insufficient distant control suggests a need for development of more active chemotherapy regimens.",
keywords = "Accelerated hyperfractionated thoracic radiation, Cisplatin, Concurrent chemoradiotherapy, Etoposide, Limited-stage small-cell lung cancer",
author = "Yoshihiko Segawa and Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Nagio Takigawa and Yoshio Hiraki and Yoichi Watanabe and Toshiro Yonei and Tomonori Moritaka and Junichiro Hiyama and Shunkichi Hiraki and Mitsune Tanimoto and Mine Harada",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0169-5002(03)00139-9",
language = "English",
volume = "41",
pages = "13--20",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer

AU - Segawa, Yoshihiko

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Takigawa, Nagio

AU - Hiraki, Yoshio

AU - Watanabe, Yoichi

AU - Yonei, Toshiro

AU - Moritaka, Tomonori

AU - Hiyama, Junichiro

AU - Hiraki, Shunkichi

AU - Tanimoto, Mitsune

AU - Harada, Mine

PY - 2003/7/1

Y1 - 2003/7/1

N2 - To improve the efficacy of a combination of cisplatin and etoposide and concurrent accelerated twice-daily thoracic radiotherapy against limited-stage small-cell lung cancer, we conducted a phase I/II study using an altered schedule of chemotherapy administration. Chemotherapy consisted of four cycles of cisplatin (days 1 and 8) and etoposide (days 1, 2, 8, and 9) every 4 weeks. Accelerated hyperfractionated thoracic radiation (1.5 Gy twice daily×30 fractions, total dose of 45 Gy) was concurrently given with the first cycle of chemotherapy. The recommended doses of cisplatin and etoposide determined in the phase I study were 40 and 80 mg/m2, respectively. In the phase II study, the overall response rate was 100% (complete response: 32%, partial response: 68%). By a median follow-up time of 29 months, median radiation-outfield progression-free survival was 13.4 months, while radiation-infield progression-free survival did not reach median value. The median overall survival time was 22.9 months, with survival rate of 48.4% at 2 years. Major toxicities were leukopenia and neutropenia (≥grade 3, 92% each). The local control and overall survival demonstrated in this study were excellent. However, the insufficient distant control suggests a need for development of more active chemotherapy regimens.

AB - To improve the efficacy of a combination of cisplatin and etoposide and concurrent accelerated twice-daily thoracic radiotherapy against limited-stage small-cell lung cancer, we conducted a phase I/II study using an altered schedule of chemotherapy administration. Chemotherapy consisted of four cycles of cisplatin (days 1 and 8) and etoposide (days 1, 2, 8, and 9) every 4 weeks. Accelerated hyperfractionated thoracic radiation (1.5 Gy twice daily×30 fractions, total dose of 45 Gy) was concurrently given with the first cycle of chemotherapy. The recommended doses of cisplatin and etoposide determined in the phase I study were 40 and 80 mg/m2, respectively. In the phase II study, the overall response rate was 100% (complete response: 32%, partial response: 68%). By a median follow-up time of 29 months, median radiation-outfield progression-free survival was 13.4 months, while radiation-infield progression-free survival did not reach median value. The median overall survival time was 22.9 months, with survival rate of 48.4% at 2 years. Major toxicities were leukopenia and neutropenia (≥grade 3, 92% each). The local control and overall survival demonstrated in this study were excellent. However, the insufficient distant control suggests a need for development of more active chemotherapy regimens.

KW - Accelerated hyperfractionated thoracic radiation

KW - Cisplatin

KW - Concurrent chemoradiotherapy

KW - Etoposide

KW - Limited-stage small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0037783862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037783862&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(03)00139-9

DO - 10.1016/S0169-5002(03)00139-9

M3 - Article

C2 - 12826307

AN - SCOPUS:0037783862

VL - 41

SP - 13

EP - 20

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -